TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC

NCT ID: NCT06914297

Last Updated: 2025-04-30

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-04-21
• Study Completion Date: 2029-04-01

Brief Summary

Based on the above situation, the investigators propose the following scientific hypothesis: In young patients with early MMRd type EC, the use of immune checkpoint inhibitors combined with progesterone for fertility retention therapy can improve the therapeutic efficacy, reduce recurrence, and improve tumor prognosis.

Based on the above assumptions, this project intends to conduct a prospective exploratory clinical study in EC patients limited to the endometrial layer or superficial myometrium (FIGO 2023 IA1-IA2 stage). The subjects were treated with TQB2450 periodic intravenous drip + high-potency progesterone daily oral therapy. During the treatment period, hysteroscopy was performed every 12 weeks to evaluate the therapeutic efficacy. The primary endpoint was the 12-week CR rate; the secondary endpoints included the 24-week CR rate, the 36-week CR rate, the median CR time, the 1-year relapse rate, the 2-year relapse rate, the median relapse time, the pregnancy rate, the live birth rate, and drug-related adverse reactions. The exploratory indicators were the response of different MMRd tumors to immune checkpoint inhibitors and their possible mechanisms. The development of this study will provide a clinical basis for improving the fertility-preserving treatment regimen of MMRd EC.

Detailed Description

The incidence of endometrial cancer (EC) is on the rise and tends to be younger. With the release of China's multi-child policy and the delay of marriage and childbearing age in modern society, many endometrial cancer patients still have an urgent need to have children when they are found to be suffering from the disease. The standard treatment of EC is total hysterectomy, which makes women permanently lose their fertility. Therefore, the treatment of young EC patients with fertility preservation has become a new focus in the field of tumor reproduction. Conservative treatment based on large dose of progesterone is a classic treatment for early EC fertility preservation. For patients who meet the nursing standards, the complete response rate is 70-80%. This research group comprehensively evaluated the complete response rate of combined drug nursing treatment by hysteroscopy to reach 95%. However, it was also observed that about 1/3 of nurse-care patients had been treated for more than 9 months or continued to fail to achieve complete response (CR). Due to the prolonged duration of treatment, multiple hysteroscopic assessments during treatment increase the risk of endometrial injury, while long-term use of large doses of progesterone may lead to ovarian function suppression, all of which affect the success rate of pregnancy after complete remission. In addition, long-term oral large dose of progesterone can lead to increased risk of weight gain, liver function impairment, thrombosis, breast cancer, etc. Dizziness, headache and digestive tract symptoms during medication also affect patients' quality of life and reduce patients' treatment compliance. How to further optimize the early EC nursing treatment program, shorten the treatment time required to achieve complete remission, reduce adverse reactions, and improve the pregnancy rate after complete remission has become a new important topic facing EC nursing treatment.

The establishment of EC molecular typing provides a possibility for promoting EC precision therapy and improving patients' quality of life and prognosis. EC molecular typing has been proposed for more than 10 years, and endometrial cancer can be divided into four different types based on tumor molecular characteristics without any dependence on tumor morphological characteristics: POLE hypermutation (POLEmut), mismatch repair deficiency (MMRd), p53 abnormal, p53abn and no specific molecular profile (NSMP). Previous studies have confirmed high consistency between diagnostic endometrial specimens (biopsy or curettage) and whole uterine specimens. Molecular typing is helpful to predict the efficacy of endocrine therapy and has important reference value for judging whether patients of childbearing age can be treated with fertility preservation function.

MMRd type EC is relatively insensitive to progesterone therapy, and the selection of its treatment regimen is an important challenge for EC fertility-preserving therapy. MMRd type EC accounts for about 5% -16% of patients on fertility-preserving therapy. It has been reported that the remission rate of progesterone therapy in MMRd type EC and endometrial atypical hyperplasia patients is significantly lower than that in mismatch repair system intact type. In 2021, the first study on the effect of molecular typing on the prognosis of EC patients was published in South Korea. It was found that the overall progesterone response rate and the complete remission rate of disease at 6 months in MMRd type patients were significantly lower than those in p53 wild type patients. And even after complete remission, the recurrence rate of MMRd patients is higher. It is speculated that the reason may be that the tumor in this type of patients activates non-progesterone receptor-dependent molecular pathways, which in turn affects the focus's response to progesterone. For MMRd EC, it is necessary to explore new treatment options to improve the overall efficacy of EC care therapy.

Immune checkpoint inhibitors (ICIs) may be an effective treatment option to shorten the duration and improve the curative effect of MMRd-type EC. MMRd tumors have high tumor mutation burden caused by microsatellite instability (MSI-H) and are accompanied by a large number of tumor neoantigens and immune cell infiltration. Pathological features such as high tumor mutation burden and a large number of tumor neoantigens and immune cell infiltration provide feasibility for immunotherapy, among which programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) inhibitors are one of the most popular targets of immunotherapy, and preliminary evidence confirms that they have clinical benefits for MMRd-type EC. In 2019, pembrolizumab was recommended by NCCN guidelines as an effective regimen for the systemic treatment of relapsed, metastatic, and high-risk EC in MSI-H/MMRd. Nivolumab, dostarlimab, and avelumab have also been confirmed to be effective in the treatment of EC, and are recommended in NCCN guidelines for second-line treatment in patients with relapsed and metastatic EC. The KEYNOTE-158 study enrolled 90 treated patients with advanced EC in MSI-H/dMMR and found an objective response rate of 48% (95% CI, 37% to 60%) to pabolizumab, with a median follow-up of 42.6 months (6.4-56 months), a median response time not reached (NR; range, 2.9-≥ 49.7 + months), a median progression-free survival time of 13.1 months (95% CI, 4.3-34 months), and a median overall survival time not reached; these results confirm that pabolizumab has effective and long-lasting antitumor activity, a favorable survival outcome, and controlled toxicity. In 2023, two high-quality randomized controlled clinical studies, NRG-GY018 and RUBY, both published results, confirming that the combination of anti-PD-1 inhibitors on the basis of platinum-containing chemotherapy can significantly improve the prognosis of locally advanced, metastatic or recurrent EC, especially in the dMMR population. After the publication of the two studies, pabolizumab and dotalizumab have been recommended by NCCN guidelines as the first-line systemic treatment regimen for advanced, metastatic or recurrent EC. ICIs have good anti-tumor effect in patients with advanced, metastatic or recurrent EC of MMRd type, but the efficacy in patients with MMRd type EC with retained fertility function still needs more research to confirm.

Case reports suggest that ICIs can be beneficial for fertility-preserving treatment of MMRd EC. Di Cao et al. reported a 36-year-old patient with Lynch syndrome, diagnosed with endometrioid carcinoma and colon cancer, who achieved complete tumor remission after treatment with sintilizumab, followed by successful pregnancy and live birth; no obvious adverse drug reactions were seen during the 11-month follow-up. Our research group has previously performed experimental ICI treatment on four patients with Lynch syndrome-related MMRd EC, and all four patients achieved complete remission. The treatment time was 18-42 weeks, and no tumor recurrence was seen during the follow-up period.

Benmelstobart (TQB2450) is a humanized monoclonal antibody that targets PD-L1, preventing PD-L1 from binding to the PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity, thereby enhancing the immune response, and has the potential to treat many types of tumors. Molecular formula: C6444H9968N1692O2002S46, molecular weight: 144,651 Da (non-glycosylation). There are currently 22 clinical studies registered, 6 of which are Phase III clinical trials.

Based on the above situation, we propose the following scientific hypothesis: In young patients with early MMRd type EC, the use of immune checkpoint inhibitors combined with progesterone for fertility retention therapy can improve the therapeutic efficacy, reduce recurrence, and improve tumor prognosis.

Based on the above assumptions, this project intends to conduct a prospective exploratory clinical study in EC patients limited to the endometrial layer or superficial myometrium (FIGO 2023 IA1-IA2 stage). The subjects were treated with TQB2450 periodic intravenous drip + high-potency progesterone daily oral therapy. During the treatment period, hysteroscopy was performed every 12 weeks to evaluate the therapeutic efficacy. The primary endpoint was the 12-week CR rate; the secondary endpoints included the 24-week CR rate, the 36-week CR rate, the median CR time, the 1-year relapse rate, the 2-year relapse rate, the median relapse time, the pregnancy rate, the live birth rate, and drug-related adverse reactions. The exploratory indicators were the response of different MMRd tumors to immune checkpoint inhibitors and their possible mechanisms. The development of this study will provide a clinical basis for improving the fertility-preserving treatment regimen of MMRd EC.

Conditions

Endometrial Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ICI plus P

Initial hysteroscopic lesion resection and endometrial pathological evaluation were performed in patients who met the nanoparticle criteria, and drug therapy was initiated within one week: TQB2450 (1200 mg q3w ivgtt) + meprogesterone acetate (MA, 160 mg qdpo)/medroxyprogesterone acetate (MPA, 500 mg qdpo). Comprehensive/individualized hysteroscopic evaluation was performed at 12 weeks of treatment. According to the endometrial pathological results, radical surgery was recommended if the disease progressed (PD); if complete response/partial response (PR)/stable disease (SD) was achieved, the above regimen was continued with TQB2450 + MA/MPA. After 12 weeks of treatment, hysteroscopic comprehensive/individualized evaluation was performed again. According to the endometrial pathological results, if PR/SD/PD, radical surgical treatment was recommended. After treatment reached CR, the above regimen was continued to TQB2450 + MA/MPA consolidation treatment for 12 weeks.

Group Type: EXPERIMENTAL

TQB2450 injection + oral progestin

Intervention Type: DRUG

TQB2450 (1200 mg q3w ivgtt) + megestrol acetate (MA, 160 mg qd po)/megestrol acetate (MPA, 500 mg qd po)

Interventions

TQB2450 injection + oral progestin

TQB2450 (1200 mg q3w ivgtt) + megestrol acetate (MA, 160 mg qd po)/megestrol acetate (MPA, 500 mg qd po)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age range from 18 to 45 years.

2. Pathological diagnosis of endometrioid carcinoma by biopsy, diagnostic curettage or hysteroscopy, non-invasive (G1-2); clinical diagnosis by G1-2); clinical diagnosis confirmed by at least two associate senior physicians;

3. Run possible, unknown EC;

4. Intense MRI, enhanced MMRI, enhanced MRI/CT, and pulmonary CT, or PET/CT assessments indicated that the lesions were limited to the endometrial layer or superficial myometrium, and there was no clear deep myometrium, cervix, or extrauterine involvement.

5. , WHFIGO 2023 IA1-IA2;

6. EC molecular typing, resulting in MMRd type (molecular typing is based on the World Health Organization (WHO) classification criteria for female genital tumors (5th edition) );

7. Those who require or insist on preserving reproductive function, or those who insist on preserving the uterus despite having no fertility requirements.

informed

Exclusion Criteria

9. and can be followed up regularly in this hospital.

1. Endometrioid carcinoma FIGO grade G3, type II EC (including serous carcinoma, clear cell carcinoma, carcinosarcoma, undifferentiated carcinoma, dedifferentiated carcinoma, neuroendocrine carcinoma, etc.), or other non-epithelial uterine malignancies (adenosarcoma, stromal sarcoma, etc.);

2. Imaging evaluation indicates deep myometrial involvement, cervical involvement, or the possibility of extrauterine metastases.

3. History of important organ transplantation;

4. Uncontrolled diseases or active infections;

5. Concomitant with severe acute diseases such as stroke, myocardial infarction, etc.

6. Other malignant tumors of the reproductive system (except in patients with Lynch syndrome who also have ovarian cancer).

7. Those who require hysterectomy or other methods of treatment other than conservative medication.

8. Pregnant persons;

9. Those who have received conservative treatment (or medication maintenance treatment) with high-potency progesterone or oral contraceptives for more than 1 month due to endometrial hyperplasia in the past three months;

10. Smoking history, those who smoke more than 15 cigarettes per day;

11. Those who are contraindicated in the use of immunosuppressants or progesterone.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Fudan University

OTHER

Sponsor Role: lead

Responsible Party

Xiaojun Chen

Vice President, Tenth People's Hospital of Tongji University, Shanghai, China

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Yu Xue, M.D

Role: STUDY_DIRECTOR

Obstetrics & Gynecology Hospital of Fudan University

Locations

Tenth People's Hospital of Tongji University

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Xiaojun Chen, Ph.D, M.D

Role: CONTACT

cxjlhjj@163.com

862133189900

Yu Xue, M.D

Role: CONTACT

xueyu_shuang@163.com

862163455050

Facility Contacts

Yu Xue

Role: primary

xueyu_shuang@163.com

86-13918803650

Other Identifiers

FST-dMMR-ICIs

Identifier Type: -

Identifier Source: org_study_id